Neuphoria Therapeutics Inc - Asset Resilience Ratio
Neuphoria Therapeutics Inc (NEUP) has an Asset Resilience Ratio of 0.60% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2021)
This chart shows how Neuphoria Therapeutics Inc's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Neuphoria Therapeutics Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Neuphoria Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Neuphoria Therapeutics Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $327.31K | 0.6% |
| Total Liquid Assets | $327.31K | 0.60% |
Asset Resilience Insights
- Limited Liquidity: Neuphoria Therapeutics Inc maintains only 0.60% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Neuphoria Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Neuphoria Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Neuphoria Therapeutics Inc (2012–2021)
The table below shows the annual Asset Resilience Ratio data for Neuphoria Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-06-30 | 0.80% | $327.31K | $40.77 Million | -0.22pp |
| 2019-06-30 | 1.02% | $385.19K | $37.58 Million | +0.18pp |
| 2018-06-30 | 0.85% | $404.02K | $47.80 Million | +0.19pp |
| 2017-06-30 | 0.65% | $422.65K | $64.61 Million | +0.03pp |
| 2016-06-30 | 0.62% | $410.73K | $65.72 Million | -0.17pp |
| 2015-06-30 | 0.80% | $421.85K | $53.02 Million | +0.68pp |
| 2012-06-30 | 0.11% | $36.23K | $31.83 Million | -- |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disord… Read more